InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.13
(
1.07%
)
US TECH 100
18,744.80
(
0.00%
)
Dow Jones
40,861.71
(
0.31%
)
Brent Oil
71.33
(
1.15%
)
Bitcoin
58,252.98
(
1.58%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rocky301

Send PM Follow Ignore
Followers 110
Posts 6480
Boards Moderated 0
Alias Born 05/01/2003

rocky301

Re: interstate post# 25270

Tuesday, 11/30/2010 1:40:31 PM

Tuesday, November 30, 2010 1:40:31 PM

Post# of 92948
interstate,

"That change would allow ACT's five single-blastomere lines currently under review at the NIH to receive federal funding for research, if approved by the agency. ACT currently has an investigational new drug application (IND) under review at the FDA for a Phase I/II trial using its MA09 single-blastomere line to treat Stargardt disease, a genetic condition and the leading cause of juvenile blindness in the U.S., Lanza told BioWorld Today."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46950661&txt2find=MA09

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up